PURPOSE: Though C-C chemokine ligand 2 (CCL2) has been shown to play a pivotal role in prostate cancer tumorigenesis and invasion, the role of inherited variation in the CCL2 gene in prostate cancer progression and metastases remains unanswered. This study is aimed to determine the influence of CCL2 germline variants on prostate cancer aggressiveness. EXPERIMENTAL DESIGN: We performed an association study between six single nucleotide polymorphisms (SNP) in the CCL2 gene and prostate cancer clinicopathologic variables in a large hospital-based Caucasian patient cohort (N = 4,073). RESULTS: Genetic variation at CCL2 is associated with markers of disease aggressiveness. Three SNPs, each in strong linkage disequilibrium, are associated with a higher (>7) biopsy Gleason score: CCL2 -1811 A/G, -2835 A/C, and +3726 T/C (P = 0.01, 0.03, and 0.04, respectively). The CCL2 -1811 G allele is additionally associated with advanced pathologic stages in patients who underwent radical prostatectomy (P = 0.04). In haplotype analysis, we found that the frequency of a common haplotype, H5, was higher among patients with D'Amico good risk features (P(permutation) = 0.04). CONCLUSIONS: These results support the influence of CCL2 variants on prostate cancer development and progression.
PURPOSE: Though C-C chemokine ligand 2 (CCL2) has been shown to play a pivotal role in prostate cancer tumorigenesis and invasion, the role of inherited variation in the CCL2 gene in prostate cancer progression and metastases remains unanswered. This study is aimed to determine the influence of CCL2 germline variants on prostate cancer aggressiveness. EXPERIMENTAL DESIGN: We performed an association study between six single nucleotide polymorphisms (SNP) in the CCL2 gene and prostate cancer clinicopathologic variables in a large hospital-based Caucasian patient cohort (N = 4,073). RESULTS: Genetic variation at CCL2 is associated with markers of disease aggressiveness. Three SNPs, each in strong linkage disequilibrium, are associated with a higher (>7) biopsy Gleason score: CCL2-1811 A/G, -2835 A/C, and +3726 T/C (P = 0.01, 0.03, and 0.04, respectively). The CCL2 -1811 G allele is additionally associated with advanced pathologic stages in patients who underwent radical prostatectomy (P = 0.04). In haplotype analysis, we found that the frequency of a common haplotype, H5, was higher among patients with D'Amico good risk features (P(permutation) = 0.04). CONCLUSIONS: These results support the influence of CCL2 variants on prostate cancer development and progression.
Authors: David H McDermott; Qiong Yang; Sekar Kathiresan; L Adrienne Cupples; Joseph M Massaro; John F Keaney; Martin G Larson; Ramachandran S Vasan; Joel N Hirschhorn; Christopher J O'Donnell; Philip M Murphy; Emelia J Benjamin Journal: Circulation Date: 2005-08-23 Impact factor: 29.690
Authors: William K Oh; Julia Hayes; Carolyn Evan; Judith Manola; Daniel J George; Helen Waldron; Meaghan Donovan; John Varner; John Orechia; Beth Katcher; Diana Lu; Arthur Nevins; Renée L Wright; Lauren Tormey; James Talcott; Mark A Rubin; Massimo Loda; William R Sellers; Jerome P Richie; Philip W Kantoff; Jane Weeks Journal: Clin Genitourin Cancer Date: 2006-06 Impact factor: 2.872
Authors: Marcus Mühlbauer; Anja K Bosserhoff; Arndt Hartmann; Wolfgang E Thasler; Thomas S Weiss; Hans Herfarth; Guntram Lock; Jürgen Schölmerich; Claus Hellerbrand Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Irene Brana; Antonio Calles; Patricia M LoRusso; Lorrin K Yee; Thomas A Puchalski; Shobha Seetharam; Bob Zhong; Carla J de Boer; Josep Tabernero; Emiliano Calvo Journal: Target Oncol Date: 2014-06-15 Impact factor: 4.493
Authors: Tong Sun; William K Oh; Susanna Jacobus; Meredith Regan; Mark Pomerantz; Matthew L Freedman; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Cancer Prev Res (Phila) Date: 2011-09-07
Authors: Jeannette T Bensen; Zongli Xu; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jack A Taylor Journal: Prostate Date: 2012-05-01 Impact factor: 4.104
Authors: Peter S Kirk; Theodore Koreckij; Holly M Nguyen; Lisha G Brown; Linda A Snyder; Robert L Vessella; Eva Corey Journal: Int J Mol Sci Date: 2013-05-21 Impact factor: 5.923